World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
51134
World Ranking
12899
National Ranking
1210

Overview

Ian Chau is affiliated with the Royal Marsden NHS Foundation Trust in the United Kingdom and has a significant body of work in oncology and related medical fields. Their research spans multiple areas within medicine, with a primary focus on cancer treatment and diagnostics.

The main field of study for Ian Chau is Medicine, with 575 publications. Subfields of their research include Oncology, Pulmonary and Respiratory Medicine, Surgery, Pathology and Forensic Medicine, and Cancer Research.

Ian Chau's research interests cover a variety of cancer-related topics, notably:

  • Gastric Cancer Management and Outcomes
  • Esophageal Cancer Research and Treatment
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Pancreatic and Hepatic Oncology Research
  • Genetic factors in colorectal cancer

They have frequently published in several key journals, including:

  • Annals of Oncology (46 publications)
  • Journal of Clinical Oncology (46 publications)
  • ESMO Open (7 publications)
  • British Journal of Haematology (7 publications)
  • Gastric Cancer (5 publications)

Ian Chau has collaborated extensively with other researchers. Frequent co-authors include:

  • David Cunningham (104 joint publications)
  • Naureen Starling (87 joint publications)
  • Ruwaida Begum (38 joint publications)
  • Sheela Rao (36 joint publications)
  • David Watkins (26 joint publications)

Selected recent papers by Ian Chau include:

  • Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines, 2021, Annals of Oncology
  • Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials, 2021, JAMA Oncology
  • Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study, 2023, The Lancet Oncology
  • Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study, 2021, Nature Cancer
  • MRI-Diagnosed Tumor Deposits and EMVI Status Have Superior Prognostic Accuracy to Current Clinical TNM Staging in Rectal Cancer, 2020, Annals of Surgery

Best Publications

  • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

    David Cunningham;Yves Humblet;Salvatore Siena;David Khayat

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins

  • Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

    Charles S Fuchs;Jiri Tomasek;Cho Jae Yong;Filip Dumitru

  • Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    David M. Hyman;Igor Puzanov;Vivek Subbiah;Jason E. Faris

  • Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

    Georgios Vlachogiannis;Somaieh Hedayat;Alexandra Vatsiou;Yann Jamin

  • Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

    Scott J. Antonia;José A. López-Martin;Johanna Bendell;Patrick A. Ott

  • Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Kohei Shitara;Mustafa Özgüroğlu;Yung-Jue Bang;Maria Di Bartolomeo

  • Ramucirumab Versus Placebo as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH): A Randomised, Double-Blind, Multicentre, Phase 3 Trial

    Andrew X. Zhu;Joon Oh Park;Baek Yeol Ryoo;Chia Jui Yen

  • Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

    David Cunningham;Ian Chau;Deborah D. Stocken;Juan W. Valle

  • Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

    Tom Waddell;Ian Chau;David Cunningham;David Gonzalez

  • FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

    Mustafa Suker;Berend R Beumer;Eran Sadot;Lysiane Marthey

  • Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data

    Ian Chau;Andy R. Norman;David Cunningham;Justin S. Waters

  • Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial

    Hugo E R Ford;Andrea Marshall;John A Bridgewater;Tobias Janowitz

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

    Bryan J Schneider;Jarushka Naidoo;Bianca D Santomasso;Christina Lacchetti

  • CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

    Yelena Y. Janjigian;Johanna Bendell;Emiliano Calvo;Joseph W. Kim

  • Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer

    Ian Chau;Gina Brown;David Cunningham;Diana Tait

  • Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)

    Alice Dewdney;David Cunningham;Josep Tabernero;Jaume Capdevila

  • Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.

    Matthew T Seymour;Sarah R Brown;Gary Middleton;Timothy Maughan

  • First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

    Harpreet S Wasan;Peter Gibbs;Navesh K Sharma;Julien Taieb

  • Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial

    Yu Jo Chua;Yu Jo Chua;Yolanda Barbachano;David Cunningham;Jacqui R Oates

Frequent Co-Authors

David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust
Gina Brown
Gina Brown Imperial College London
Andrew Wotherspoon
Andrew Wotherspoon Royal Marsden NHS Foundation Trust
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Bengt Glimelius
Bengt Glimelius Uppsala University
Johanna C. Bendell
Johanna C. Bendell Sarah Cannon Research Institute
A. R. Norman
A. R. Norman Royal Marsden NHS Foundation Trust
Takuji Okusaka
Takuji Okusaka National Cancer Centre
Andrew X. Zhu
Andrew X. Zhu Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine doesn’t always mean following a single path. There are a variety of affordable online degrees and certification programs for those interested in healthcare, each offering unique career opportunities.

For medical professionals aiming for advanced practice and leadership roles, finding the cheapest dnp program can make pursuing a Doctor of Nursing Practice more accessible. Similarly, aspiring pharmacists can consider the cheapest online pharmacy school options to earn a respected qualification while managing costs.

If you prefer a technology-focused healthcare role, enrolling in a him associate degree online can be a smart move, preparing you for positions in health data and informatics. Additionally, quick-entry allied health careers are possible with programs like medical billing and coding online, which offer flexibility and fast-track training.

These diverse educational pathways provide great alternatives—whether you’re seeking advancement or an efficient entry into the healthcare sector.

Best Scientists Citing Ian Chau

Trending Scientists

Recently Published Articles